invIOs is a privately held BIOTECH COMPANY based in Vienna, Austria, focusing on the discovery and development of INNOVATIVE CANCER IMMUNOTHERAPIES.
Spun out of APEIRON Biologics in January 2022, invIOs seeks to develop therapies that improve and protect the lives of cancer patients. To do this, we offer unique and highly promising new treatment options in the INNOVATIVE THERAPY area of IMMUNO-ONCOLOGY.
Our highly motivated team has SIGNIFICANT EXPERTISE across the entire biotechnology value chain. We are pioneers in researching and developing drug candidates in CELL THERAPIES targeting new immune checkpoints and in immunomodulation.